Amarin Corp. (AMRN) Misses Q4 EPS by 4c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amarin Corp. (AMRN) Begins Final Clinical Site Visits in the REDUCE-IT Cardiovascular Outcomes Study
March 1, 2018 5:52 AM ESTAmarin Corporation plc (NASDAQ: AMRN) today announced that final study-related visits have commenced for patients enrolled in its REDUCE-IT cardiovascular outcomes study. An important step in completion of this potentially landmark study is to have patients return to their clinical sites for final study data... More
